Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arterial Thrombosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

Study of the CAT RX Aspiration Catheter When Used in Patients With Large Occlusive Thrombus in Coronary Arteries

NCT03957473
View directory record Official record
Conditions
Coronary Vessel Occlusion
Interventions
Indigo Aspiration System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

NCT01638507
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational

Drug Eluting Stent Registry of Thrombosis

NCT00812552
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Sacramento, California • Washington D.C., District of Columbia • Springfield, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 22, 2026, 3:33 AM EDT
Withdrawn Phase 4 Interventional

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

NCT01826175
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Optical Coherence Tomography
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 3 Interventional

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

NCT00600327
View directory record Official record
Conditions
Transient Ischemic Attack, Thromboembolic Stroke, Stroke Prevention
Interventions
EndoTex™ NexStent™, Filter Wire EZ™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

NCT00499902
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Reversing Ticagrelor's Effects With Fresh Platelets

NCT02201394
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor loading dose, Aspirin loading dose, Ticagrelor maintenance dose, Aspirin maintenance dose
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional

Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment

NCT05411315
View directory record Official record
Conditions
Mechanical Ventilation Complication, Arterial Thrombosis, Limb Ischemia, Shock, Hypotension, Bloodstream Infection, Vasopressor Adverse Reaction, Renal Failure
Interventions
Restricted-use of arterial catheter, Standard-use of arterial catheter
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational

Platelet Sub-study of the TWILIGHT Trial

NCT04001374
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Ticagrelor, ASA
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 22, 2026, 3:33 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

NCT04768036
View directory record Official record
Conditions
Venous Thromboembolism, Arterial Thromboembolism
Interventions
IMPROVE DD VTE Tool
Other
Lead sponsor
Northwell Health
Other
Eligibility
60 Years and older
Enrollment
10,699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jul 22, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

NCT00742612
View directory record Official record
Conditions
Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions
ARC1779 Injection, Placebo (normal saline)
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting Not applicable Interventional

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

NCT06374277
View directory record Official record
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Hialeah, Florida • North Miami Beach, Florida • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 3:33 AM EDT
Completed No phase listed Observational

Safety and Feasibility of the Infinity Catheter for Radial Access

NCT04553549
View directory record Official record
Conditions
Brain Tumor, Stroke, Acute, Brain Aneurysm, Intracranial Arteriovenous Malformations, Carotid Stenosis, Cavernous Sinus Thrombosis
Interventions
Transradial approach
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 22, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nattokinase Atherothrombotic Prevention Study

NCT02080520
View directory record Official record
Conditions
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Interventions
Nattokinase, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 100 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Jul 22, 2026, 3:33 AM EDT